A key remaining hypothesis to be tested in human efficacy studies is whether high‐frequency cytotoxic effector memory CD8+ T cells available at the site of virus entry, in combination with cross‐reactive neutralizing Ab titres against multiple bnAb epitopes, could block or suppress nascent HIV replication resulting in the prevention of persistent HIV infection. Here, CD8A is linked to HIV infectious disease.